Long-acting amylin analogues for the management of obesity
Research output: Contribution to journal › Journal article › Research › peer-review
PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight. Activity at the calcitonin and amylin receptors in the area postrema seems to - at least partly - be responsible for these effects of amylin. Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity. Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide. SUMMARY: Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.
Original language | English |
---|---|
Journal | Current Opinion in Endocrinology, Diabetes and Obesity |
Volume | 29 |
Issue number | 2 |
Pages (from-to) | 183-190 |
Number of pages | 8 |
ISSN | 1752-296X |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ID: 299505700